Control of tonic-clonic seizures (grand mal epilepsy), partial seizures (focal including temporal lobe) or a combination of these, and for the prevention and treatment of seizures occurring during or following neurosurgery and/or severe head injury. Epanutin has also been employed in the treatment of trigeminal neuralgia but it should only be used as second line therapy if carbamazepine is ineffective or patients are intolerant to carbamazepine.
Pro-Epanutin is indicated in adults and children aged 5 years and older: • for the control of status epilepticus of the tonic-clonic (grand mal) type (see section 4.2). • for prevention and treatment of seizures occurring in connection with neurosurgery and/or head trauma. • as substitute for oral phenytoin if oral administration is not possible and/or contra-indicated.
The FDA has approved Fycompa (perampanel) CIII Oral Suspension, from Eisai, as adjunctive therapy for the treatment of partial-onset seizures...
Neos Therapeutics, Inc. announced that the FDA has approved Adzenys ER (amphetamine) Extended-Release Oral Suspension. Neos Therapeutics is the only...
ITF Pharma announced that the FDA has approved Tiglutik (riluzole) oral suspension for the treatment of amyotrophic lateral sclerosis (ALS)....
Eton Pharmaceuticals, Inc a specialty pharmaceutical company focused on developing and commercializing innovative drug products, announced it has submitted a new drug application (NDA) for zonisamide oral suspension, previously known as the company’s ET 104 product candidate, to the FDA for the treatment of partial seizures in patients with epilepsy.
Phenytoin Sodium Flynn Hard Capsules are indicated for control of tonic-clonic seizures (grand mal epilepsy), partial seizures (focal including temporal lobe) or a combination of these, and for the prevention and treatment of seizures occurring during or following neurosurgery and/or severe head injury. Phenytoin Sodium Flynn Hard Capsules has also been employed in the treatment of trigeminal neuralgia but it should only be used as second line therapy if carbamazepine is ineffective or patients are intolerant to carbamazepine.
Mitsubishi Tanabe Pharma Corporation, a member of the Mitsubishi Chemical Group, announced that MTPC obtained the regulatory approval of Radicut Oral Suspension 2.1% (generic name: edaravone) for the treatment of patients with amyotrophic lateral sclerosis (ALS) from the Ministry of Health, Labour and Welfare on December 23, 2022.